Nantahala Capital Management’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Nantahala Capital Management’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-23,830	Closed	-$397K	–	137
2022 Q1	$397K	Sell	23,830 -4,088	-15%	-$131K	0.02%	110
2021 Q4	$1.82M	Sell	27,918 -1,013	-4%	-$59K	0.06%	109
2021 Q3	$1.98M	Sell	28,931 -1,371	-5%	-$98.1K	0.06%	106
2021 Q2	$2.11M	Hold	30,302	–	–	0.06%	106
2021 Q1	$1.99M	Hold	30,302	–	–	0.06%	99
2020 Q4	$1.74M	Buy	30,302 +1,891	+7%	+$110K	0.05%	102
2020 Q3	$1.69M	Buy	28,411 +299	+1%	+$26.7K	0.05%	101
2020 Q2	$3.64M	Hold	28,112	–	–	0.11%	90
2020 Q1	$1.65M	Buy	28,112 +334	+1%	+$32.7K	0.06%	94
2019 Q4	$3.51M	Hold	27,778	–	–	0.11%	74
2019 Q3	$3.32M	Buy	+27,778	New	+$5.59M	0.12%	80

Other funds holding HTGM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Nantahala Capital Management's HTGM Position: Q2 2022 in Review

Nantahala Capital Management sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q2 2022, closing a stake of 23,830 shares — an estimated $397K sold.

Nantahala Capital Management first reported a position in HTGM in Q3 2019 and held it in 11 quarters. The position peaked at $3.64M in Q2 2020. 21 funds tracked by Wall St. Rank hold HTGM as of Q2 2022.

Nantahala Capital Management reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Nantahala Capital Management sold 23,830 HTG Molecular Diagnostics, Inc. Common Stock shares in Q2 2022, an estimated $397K.
Nantahala Capital Management first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q3 2019 and held it in 11 quarters.
Nantahala Capital Management's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $3.64M in Q2 2020.
21 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q2 2022.

Based on Nantahala Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.